Elonova is advancing a next-generation mRNA technology pipeline that integrates proprietary cap chemistry (MSCap), nucleotide modification, and 3′-end engineering.

Our R&D focuses on improving mRNA stability, translation efficiency, and immunological balance — enabling breakthrough applications in oncology.